Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Bone Loss in Anorexia Nervosa
NCT02567279Phase 3Terminated
- Sponsor
- CHU Montpellier
- Start
- Jun 2016
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab in osteoporosis, sponsored by CHU Montpellier. Started Jun 2016; status: terminated.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02567279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567279.